A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis drug Gileyna.
US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.
Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.
The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Pfizer’s attempt to secure an Arrow declaration in relation to its proposed launch of a cancer drug in Europe was shot down yesterday, June 20, by the English High Court.
Generic medicines can cost up to 30 times more in poor countries, according to a new study.
US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.
A US congressman and senator have asked the country’s audit institution, the Government Accountability Office to review the management of government-owned IP in the health sector.
Pharmaceutical companies Merck & Co, Eli Lilly, and Amgen are suing the US Department of Health and Human Services over proposed rules which would force companies to disclose the list prices of drugs in TV advertisements.